NL2011448A - Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. - Google Patents
Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. Download PDFInfo
- Publication number
- NL2011448A NL2011448A NL2011448A NL2011448A NL2011448A NL 2011448 A NL2011448 A NL 2011448A NL 2011448 A NL2011448 A NL 2011448A NL 2011448 A NL2011448 A NL 2011448A NL 2011448 A NL2011448 A NL 2011448A
- Authority
- NL
- Netherlands
- Prior art keywords
- palmitoylethanolamide
- particles
- pharmaceutical composition
- pharmaceutical
- flakes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Farmaceutische samenstelling omvattende palmitoylethanolamide deeltjes en/of farmaceutisch acceptabele esters of zouten daarvan, waarin de palmitoylethanolamide deeltjes vrij zijn van farmaceutische excipiënten, zodat de palmitoylethanolamide deeltjes geen agglomeraten vormen.
2. Farmaceutische samenstelling volgens conclusie 1, waarin de palmitoylethanolamide deeltjes een deeltjesgrootteverdeling hebben waarbij: - ten minste 99% van de deeltjes een diameter heeft tussen 1 pm en 850 pm; en - ten minste 40% van de deeltjes een diameter heeft die kleiner is dan 425 pm.
3. Farmaceutische samenstelling volgens conclusie 1 of 2, waarin de palmitoylethanolamide deeltjes vrij zijn van magnesiumstearaat, povidon, sorbitol and/of andere farmaceutische excipiënten.
4. Farmaceutische samenstelling volgens een van de conclusies 1-3, waarin de samenstelling een tweede of verdere farmaceutisch actief ingrediënt omvat voor het verminderen van pijn en/of ontsteking.
5. Farmaceutische samenstelling volgens conclusie 4, waarin het tweede of verdere farmaceutisch actieve ingrediënt theanine, vitamine D, glucosamine, Boswellia extracten, vanadium zouten zoals bis(maltolato)oxovanadium (BMOV), of picamilon is.
6. Farmaceutische samenstelling volgens één van de voorgaande conclusies, waarin de samenstelling wordt verschaft in capsule of sachet.
7. Farmaceutische samenstelling volgens één van de voorgaande conclusies voor gebruik in de behandeling of voor gebruik in de preventie van immuun of chronische ontstekingsaandoeningen, neuro-ontstekingen of chronische pijn aandoeningen in zoogdieren, bijvoorkeur mensen.
8. Werkwijze voor het vervaardigen van palmitoylethanolamide deeltjes, waarin de deeltjes vrij zijn van farmaceutisch acceptabele excipiënten, omvattende de volgende stappen: i) verschaffen van palmitoylethanolamide vlokken; ii) verkleinen, snijden of malen van de palmitoylethanolamide vlokken in palmitoylethanolamide deeltjes in de afwezigheid van farmaceutische excipiënten, op een dusdanige manier dat de deeltjes die zijn verkregen een deeltjesgrootteverdeling hebben waarin: - ten minste 99% van de deeltjes een diameter heeft tussen 1 pm en 850 pm, - ten minste 40% van de deeltjes een diameter heeft die kleiner is dan 425 pm.
9. Werkwijze volgens conclusie 8, waarbij het verkleinen van de palmitoylethanolamide vlokken wordt uitgevoerd bij een temperatuur van min 20 tot min 200°C, bij voorkeur min 100 tot min 200°C, meest bij voorkeur min 190 tot min 200°C.
10. Werkwijze volgens conclusie 9, waarin het verkleinen van de palmitoylethanolamide vlokken wordt uitgevoerd in de aanwezigheid van vloeibare stikstof.
11. Werkwijze volgens een van de conclusies 8-10, waarin het verkleinen van de palmitoylethanolamide vlokken wordt uitgevoerd in een oscillerende en roterende zeefmolen of hamermolen, of enig ander daarvoor geschikte molen, bij kamertemperatuur.
12. Palmitoylethanolamide deeltjes verkrijgbaar met de werkwijze zoals beschreven in één van de conlusies 8-11.
13. Farmaceutische samenstelling omvattende de palmitoylethanolamide deeltjes volgens conclusie 12.
14. Farmaceutische samenstelling omvattende palmitoylethanolamide zoals beschreven in één van de conlusies 8-13, opgelost in een basis voor crème bestaande uit alleen cetomacrogol, cetostearyl-alcohol, cetiol en sorbitol (cremor cetomacrogolis), of in combinatie met 1-theanine, bis(maltolato)oxovanadium (BMOV), Boswellia serrata extracten en/of co-analgesica zoals amitriptyline, baclofen en ketamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2011448A NL2011448C2 (en) | 2012-09-17 | 2013-09-16 | Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2009474 | 2012-09-17 | ||
| NL2009474 | 2012-09-17 | ||
| NL2011448A NL2011448C2 (en) | 2012-09-17 | 2013-09-16 | Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. |
| NL2011448 | 2013-09-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL2011448A true NL2011448A (en) | 2014-03-18 |
| NL2011448C2 NL2011448C2 (en) | 2015-01-29 |
Family
ID=50679570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL2011448A NL2011448C2 (en) | 2012-09-17 | 2013-09-16 | Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. |
Country Status (1)
| Country | Link |
|---|---|
| NL (1) | NL2011448C2 (nl) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016063217A1 (en) * | 2014-10-22 | 2016-04-28 | Raffaele Migliaccio | Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions |
| WO2016146453A1 (en) * | 2015-03-16 | 2016-09-22 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain |
| NL2017559B1 (en) * | 2016-09-30 | 2018-04-10 | Vanderbilt Science Holding Ltd | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles |
| US10350179B2 (en) | 2015-06-04 | 2019-07-16 | Raffaele Migliaccio | Combination comprising palmitoylethanolamide (PEA) and lycopene for use in the treatment of inflammatory diseases |
| CN112121041A (zh) * | 2019-06-24 | 2020-12-25 | 湖南方升泰医药科技有限公司 | 金属络合物的新应用 |
| US10973782B2 (en) | 2017-09-05 | 2021-04-13 | Frimline Private Limited | Pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| IT202200017820A1 (it) | 2022-08-30 | 2024-03-01 | Unifarco S P A | Compressa nutraceutica comprendente palmitoiletanolamide |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2580508B1 (es) * | 2016-04-11 | 2018-09-12 | Servicio Andaluz De Salud | Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol. |
-
2013
- 2013-09-16 NL NL2011448A patent/NL2011448C2/en active
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016063217A1 (en) * | 2014-10-22 | 2016-04-28 | Raffaele Migliaccio | Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions |
| US10646523B2 (en) | 2014-10-22 | 2020-05-12 | Again Life Italia Srl | Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions |
| US11311581B2 (en) | 2014-10-22 | 2022-04-26 | Again Life Italia Srl | Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions |
| EA038593B1 (ru) * | 2014-10-22 | 2021-09-21 | Эген Лайф Италия Срл | Состав, содержащий спирулину и пальмитоилэтаноламид и/или их фармацевтически приемлемые соли, и его применение в профилактике и лечении состояний гиперактивированных тканей |
| WO2016146453A1 (en) * | 2015-03-16 | 2016-09-22 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain |
| NL2014464A (en) * | 2015-03-16 | 2016-10-10 | Vanderbilt Science Holding Ltd | Composition for use in the treatment of neuropathic pain. |
| US10987323B2 (en) | 2015-06-04 | 2021-04-27 | Ali Research Srls | Combination comprising palmitoylethanolamide (PEA) and lycopene for use in the treatment of inflammatory diseases |
| US10350179B2 (en) | 2015-06-04 | 2019-07-16 | Raffaele Migliaccio | Combination comprising palmitoylethanolamide (PEA) and lycopene for use in the treatment of inflammatory diseases |
| NL2017559B1 (en) * | 2016-09-30 | 2018-04-10 | Vanderbilt Science Holding Ltd | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles |
| US10973782B2 (en) | 2017-09-05 | 2021-04-13 | Frimline Private Limited | Pharmaceutical composition for improving or preventing progression of chronic kidney disease |
| CN112121041A (zh) * | 2019-06-24 | 2020-12-25 | 湖南方升泰医药科技有限公司 | 金属络合物的新应用 |
| IT202200017820A1 (it) | 2022-08-30 | 2024-03-01 | Unifarco S P A | Compressa nutraceutica comprendente palmitoiletanolamide |
| EP4331577A1 (en) | 2022-08-30 | 2024-03-06 | Unifarco S.p.A. | A nutraceutic tablet comprising palmitoylethanolamide |
Also Published As
| Publication number | Publication date |
|---|---|
| NL2011448C2 (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL2011448C2 (en) | Pharmaceutical or neutraceutical composition comprising palmitoylethanolamide particles. | |
| ES2731367T3 (es) | Formulaciones de cannabinoides sólidas orales, métodos para producir y utilizar las mismas | |
| JP3522220B2 (ja) | 細胞媒介性免疫病の処置 | |
| AU2018100110A4 (en) | Ubiquinone And Ubiquinol Compositions, And Methods Relating Thereto | |
| JP7281815B2 (ja) | 医薬化合物及び栄養補給剤 | |
| JP2007526303A (ja) | 可溶化ｃｏｑ−１０およびカルニチン | |
| US20180055782A1 (en) | Methods of Treating Inflammatory Disorders and Global Inflammation with Compositions Comprising Phospholipid Nanoparticle Encapsulations of NSAIDS | |
| AU2021213722A1 (en) | Joint health composition and use thereof in healthy mammals | |
| JP6290896B2 (ja) | 植物性フェノール、及び好酸球性食道炎の治療若しくは予防におけるその使用 | |
| JP5138341B2 (ja) | 抗アレルギー剤 | |
| EP4161505A1 (en) | Composition for normalisation of fatty liver and method for producing the same | |
| EP2787981B1 (en) | Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules | |
| US20040146537A1 (en) | Oily wax matrix suspension formulation comprising pharmacologically active agents | |
| CA3098379A1 (en) | Bioidentical progesterone cream infused with nanoemulsified cbd | |
| JP2016531931A (ja) | カカオポリフェノール及び好酸球性食道炎の治療又は予防におけるその使用 | |
| JP2019180350A (ja) | ３−ヒドロキシイソ吉草酸含有組成物及びその製造方法 | |
| AU2021204787B2 (en) | Lipid combinations | |
| US9308261B2 (en) | Compositions and methods for treating varicose veins | |
| NL2017559B1 (en) | Method for preparing pulverized palmitoylethanolamide particles, particles obtainable by the method, and apharmaceutical or neutraceutical composition comprising saidparticles | |
| Dian et al. | Palm-based vitamin E (Tocotrienol-Rich Fraction) has excellent stability in chewable tablet after one-year of storage at ambient temperature | |
| EP4274433A1 (en) | Extended release vitamin c and manufacturing thereof | |
| WO2023150108A1 (en) | Extended release boswellic acid and manufacturing thereof | |
| JP2001187734A (ja) | ２型ｔヘルパー細胞分化抑制剤 | |
| JP2021001153A (ja) | クルクミンの新規用途 | |
| CA2886478A1 (en) | Directly compressible proprionic acid derivative particles |